essential hypertension
Conditions
Interventions
Switching from olmesartan 20mg/day or azelnidipine 16mg/day to olmesartan 20mg/azelnidipine16mg combination tablet for 12 weeks.
Sponsors
Kagoshima University Graduate School of Medical and Dental Sciences
DAIICHI SANKYO COMPANY, LIMITED
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: At provisional registration 1)Patients who have grade1 or grade2 essential hypertension 2) Patient who remedy are possible before this registration with 20 mg/day of olmesartan tablet or 16 mg/day of azelnidipine tablet more than eight weeks 3)Patients of 65 years old or older 4)Outpatients 5)The written informed consent provided by the patient At definitive registration 1)Patients who are using olmesartan 20 mg/day or azelnidipine 16 mg/day eight weeks or longer (at definitive registration) 2)Patients with insufficient hypotensive effect
Exclusion criteria
Exclusion criteria: Provisional registration 1)Patients who has moderate or high cognitive impairment (it is diagnosed by CGA7) 2)Patients who are taking dementia therapeutic drug 3)Patients with a history of brain, cardiovascular disorder within six months before informed consent 4)Patients who cannot accomplish 6 meters of walks 5)Patients who are taking an azole-based antifungal drug (itraconazole, miconazole) 6)Patients who are taking a HIV protease inhibitor (ritonavir, saquinavir, indinavir) 7)Patients who are taking a drug containing cobicistat 8)Diabetic patients who are taking an aliskiren fumarate(exclud the patients with insufficient hypotensive effect remarkably even if give other hypertensive therapy treatment) 9)Patients with history of hypersensitivity to olmesartan tablet 10)Patients with history of hypersensitivity to azelnidipine tablet 11)Patients who has possibility of pregnancy or pregnancy 12)Patients who judged that a study responsibility doctor was unsuitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient and physician's satisfaction(0week and 12week) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Patient's satisfaction and blood pressure(0week and 12week) 2)Patient's satisfaction, blood pressure(home,Office), the pulse, QOL (SF-12, VAS)(before and after the study drug administration ) 3)Physician's satisfaction(before and after the study drug administration) 4)Age division (under 75 years old, 75 years old or older) | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Ikeda
Kagoshima University Graduate School of Medical and Dental Sciences Department of cardiovascular medicine and hypertension
Outcome results
None listed